Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 8Melanoma 6Neoplasm Metastasis 5Thyroid Neoplasms 4Thyroid Cancer, Papillary 4Leukemia, Hairy Cell 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Thyroid Carcinoma, Anaplastic 2Skin Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Glioma 2Colorectal Neoplasms 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Thyroid cancer, follicular 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Noonan syndrome 3 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Bevacizumab 7Capecitabine 4Cetuximab 3trifluridine tipiracil drug combination 2Fluorouracil 2regorafenib 1irinotecan sucrosofate 1folfirinox 1balstilimab 1Vemurafenib 1Transurethral Resection of Prostate 1Tomography, X-Ray Computed 1Panitumumab 1Nivolumab 1Liver Transplantation 1Immune Checkpoint Inhibitors 1HMPL-013 1Folfox protocol 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Cancer Metastatic × Vemurafenib × 1 year × Clear all
NCT06008119 2025-09-18

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

Shanghai Kechow Pharma, Inc.

Phase 3 Recruiting
165 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡